Mental Health Clinics in Buena Vista, VA Accepting Medicare
8 Mental Health Clinics found. Showing 1 - 8
 Therapy Associates, Llc Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2161 Sycamore Ave, Buena Vista, VA 24416 Phone: 540-264-0330 |
Rockbridge Area League Of Therapists Counselor Medicare: Not Enrolled in Medicare Practice Location: 2424 Magnolia Ave, Buena Vista, VA 24416 Phone: 540-264-0100 |
Blue Ridge Psychotherapy & Consultation Associates, Pc Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2424 Magnolia Ave, Suite 1, Buena Vista, VA 24416 Phone: 540-460-3017 |
Family Preservation Services, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 2329 Chestnut Ave, Buena Vista, VA 24416 Phone: 540-248-5510 Fax: 540-248-5509 |
Familypreservation Services, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 101 Woodland Ave, Buena Vista, VA 24416 Phone: 540-248-5510 Fax: 540-248-5509 |
Family Preservation Services, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 100 Bradford Dr, Buena Vista, VA 24416 Phone: 540-248-5510 Fax: 540-248-5509 |
Family Preservation Services, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 20 Burger Cir, Buena Vista, VA 24416 Phone: 540-248-5510 Fax: 540-248-5509 |
Family Preservation Services, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 3400 Lombardy Ave, Buena Vista, VA 24416 Phone: 540-248-5510 Fax: 540-248-5509 |
News Archive
Enbrel shown to significantly reduced levels of C-reactive protein
Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group.
GI Company's Phase II study demonstrates safety of rhITF oral spray formulation
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Toshiba to showcase new cardiovascular ultrasound systems at ASE annual meeting
To improve exam efficiency and increase accuracy of cardiovascular disease diagnoses, Toshiba America Medical Systems, Inc. will showcase its AplioTM 500 CV, 300 CV and ArtidaTM ultrasound systems at this year's American Society of Echocardiography annual meeting in Minneapolis, June 29 - July 2, 2013 (Booth #415).
Weakened metabolism of immune T cells may account for serious complications in elderly
The elderly suffer more serious complications from infections and benefit less from vaccination than the general population.
› Verified 3 days ago